BCF Business Law Gino Martel explains the present environment for M&As, divestitures and out-licensing in the Canadian biotech sector, the different ways that biotech companies can commercialize their scientific successes in the current market climate, and strategies for keep scientific talent in Canada. How do mergers and acquisitions in the pharmaceutical industry in…
Biotech City The director of Biotech City in Laval, close to Montreal, discusses the advantages brought on by the cluster effect, and how this has played out at Biotech City, a government funded cluster of 80 companies and over 5,000 employees. Your background has a strong focus on business start-ups and development,…
investment The CEO of MaRS Innovation, a commercialization incubator created by 16 of Toronto’s best research institutions and supported by the government, assesses Toronto’s merits as an innovation hub, and describes several successful case studies of the way in which MaRS Innovation has helped to commercialize ideas in the pharmaceutical and…
government relations Minister Marceau addresses the changes in policy in Quebec relating to the pharmaceutical and life sciences sectors, and the incentives in place to make the state an attractive place for the future of the pharmaceutical industry. According to the Economic and Financial Profile of Quebec 2012, Quebec allocated 2.61…
CSR The President & CEO of Sanofi Canada talks candidly about the pros and cons of the current administrative setup of the Canadian healthcare sector; Concerto, an association in Quebec that puts innovative pharma alongside government and regulators, and the local implications of the global trend of diversification in Big Pharma.…
Basic Research A leading figure in the Taiwanese pharmaceutical sector, Lee divulges the practicalities behind ECFA, the free trade agreement that was signed between China and Taiwan in 2010 but has not yet come into full force; questions whether a lack of multinational investment has been a major disadvantage for Taiwan; explains…
Almirall Having only arrived on the market last year, the GM of Almirall in Canada explains the company’s regulatory struggles, the utilization of Almirall’s global R&D infrastructure in Canada as well as the company’s choice to enter the Canadian market and what products they are introducing into it. You started…
Ireland “The elements that have made Ireland attractive for decades are still here. The big difference since 2007, however, is the cost base. If you are building a pharma plant in Ireland today, it will cost 35 to 40 percent less than it did six years ago,” says Barry O’Leary,…
government relations In Taiwan, GSK recently signed Memorandum of Understanding with the National Research Program of Biopharmaceuticals (NRPB), building on research partnerships in Taiwan that include a 2007 agreement with National Taiwan University Hospital (NTU)—the first agreement of its kind—a later MoU with Taipei Veterans General Hospital, and a major 2012 collaboration…
investment Dr. Douville talks investment, the company’s role in R&D in Canada and their plans for some of their future products. You founded Milestone Pharmaceuticals in 2005, having founded Galileo Genomics and Allostera Pharma.What were the main objectives in founding Milestone? I was one of four founders of Milestone. The idea…
Aspen The Aspen Group identified Latin America as a “large developing market where it can leverage its substantial intellectual property portfolio and manufacturing infrastructure”. What was the original strategy behind getting the best from the Mexican market – specifically with the acquisition of the Latin America business from India-based Strides Arcolab…
R&D-based Pharmaceutical Association Committe You have a long experience in the Chinese pharmaceutical market, and in particular you saw it evolve tremendously over the last 10 years. From a management perspective, would you say that it is easier or harder to tackle today or a decade ago? In my view, the Chinese market is…
See our Cookie Privacy Policy Here
